Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products across key therapeutic areas, including women’s healthcare, cardiology, pain management, urology, and other specialty segments.

As of June 30, 2025, the company’s diversified product portfolio comprises 71 brands spanning multiple therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, which include vitamins, minerals, nutrition, gastrointestinal, and respiratory products.

The company operates a pan-India marketing and distribution network supported by 2,671 medical representatives across 22 states. This extensive field force enables effective engagement with healthcare professionals and hospitals, strengthening the company’s presence in the Indian Pharmaceutical Market (IPM) and ensuring deep penetration across its core therapeutic segments.

Corona Remedies has two manufacturing facilities located in Gujarat, with an aggregate installed formulation capacity of 1,285.44 million units per annum, supported by robust quality and compliance systems.

Competitive Strengths :

Second fastest-growing company among the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, positioning it well to capitalize on growth opportunities in the Indian market.

Proven ability to build a diversified product portfolio, including strong “engine” brands in targeted therapy areas.

Pan-India sales and marketing network with a strategy focused on the middle-of-the-pyramid market segment.

Quality-focused manufacturing facilities compliant with current Good Manufacturing Practices (cGMP), supported by strong research and development capabilities for differentiated pharmaceutical products.

Experienced and entrepreneurial management team, backed by marquee investors.